Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical TrialsJeff Sevigny, Jerome Barakos, Joyce Suhy et al.|Alzheimer Disease & Associated Disorders|2016Cited by 115
P1‐252: CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTSGregory Klein, Joyce Suhy, Jeff Sevigny et al.|Alzheimer s & Dementia|2014Cited by 2
O4‐07‐02: ENRICHMENT OF EARLY‐STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUSPing Chiao, Jeff Sevigny, Joyce Suhy et al.|Alzheimer s & Dementia|2014Cited by 1
P1–362: Amyloid PET screening results by APOE‐ε4 status from a phase 1b clinical study of 221AD103 in people with prodromal to mild Alzheimer's diseasePing Chiao, Jeff Sevigny, Joyce Suhy et al.|Alzheimer s & Dementia|2013Cited by 1
Amyloid PET Screening for Enrollment into Alzheimer’s Disease Clinical Trials: Initial Experience in a Phase 1b Clinical Trial (P3.207)Jeff Sevigny, Jerome Barakos, Joyce Suhy et al.|Neurology|2014Cited by 0